Dr Kiran Mazumdar with Biocon's key management team
Speaking on the occasion at Biocon's press meet, Ms Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon, said, "This rating has been done on various attributes based on research quality, clear vision and social responsibility. We are the only Indian and Asian company to make it to this list. Globally, that's a big recognition for what Biocon stands for today."
The event was also attended by Mr Peter Bains, Director, Syngene International, along with Biocon's key management team including Dr Arun Chandavarkar, Mr Murali Krishnan, Dr Abhijit Barve and Mr Rakesh Bamzai.
Dr Kiran also declared Biocon's earnings for the first half of the fiscal year during the event. She added, "Our biopharmaceuticals sector has grown significantly through our immuno-suppressants and Insulin products. It is gaining a lot of momentum in the emerging markets. Our research services has been a stellar performer in revenues, which has grown 46% in the quarter and 36% at the half year level."
Talking about ALZUMAb's launch in August 2013, Ms Shaw said, "ALZUMAb is not just a first-in-class drug, but also a potential best-in-class. We are very encouraged by its early acceptance in the Indian market. Only time will unravel how powerful the drug is."
Dr Kiran also added that diseases like multiple sclerosis will provide Biocon with a big opportunity for research, along with Vitiligo, for which it will conduct clinical trials in India.